Life science firm Jubilant & Sanofi collaborate on CNS therapeutics
Category: #health  By Mateen Dalal  Date: 2019-02-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Life science firm Jubilant & Sanofi collaborate on CNS therapeutics

Jubilant will deliver Sanofi drug discovery services with its integrated drug discovery platform.

The Bengaluru-based arm of the reputed Jubilant Life Sciences, Jubilant Biosys, has apparently declared that it has signed an integrated drug discovery collaboration with pharmaceutical company. Credible reports cite that the collaboration will focus on the domain of CNS therapeutics.

As per sources familiar with the matter, the debut collaboration with Sanofi had commenced back in 2016, targeted toward the discovery and development of small molecule inhibitors for numerous targets in metabolic disorders therapeutics.

An official press release from Jubilant Biosys claims that the collaboration in question is basically aimed to discover therapeutic small molecules which will be addressing unmet needs in neurological diseases. Jubilant Biosys reportedly, will be providing Sanofi drug discovery services with its integrated drug discovery platform in a bid to identify lead candidates.

Rita Balice-Gordon, Global Head, Rare and Neurologic Diseases Therapeutic Area, Sanofi, has been reported to state that the company has been earnestly looking forward to collaborating with Jubilant. The new partnership aptly demonstrates Sanofi’s dedicated commitment toward striving to discover novel medicines which can target neurological diseases, the needs of which are currently unmet around the globe, Balice-Gordon elaborates.

Speaking on the partnership, Marcel Velterop, President, Jubilant Drug Discovery Services & CDMO, claimed that the company is rather privileged and delighted to have been selected once more by Sanofi in order to contribute toward driving innovation to the clinic. The current achievement is undeniably testifies the high quality science and capability that Jubilant has built since the past decade, says Velterop, adding that the collaboration is perfectly aligned with Jubilant’s growth strategy and the company is totally committed to expand its world-class integrated, drug discovery capabilities.

For the record, Jubilant Biosys boasts of having depicted considerable expertise in numerous therapeutic domains, inclusive of Metabolic Disorders, Pain & Inflammation, CNS, Oncology, and many more.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Meter nabs $38Mn to scale business & support faster enterprise internet
Meter nabs $38Mn to scale business & support faster enterprise internet
By Mateen Dalal

Meter, Inc., an internet & Wi-Fi infrastructure provider for businesses, has recently announced that it has successfully raised $38 million in a Series B funding round that was headed by Lachy Groom and Sequoia Capital. Industry leaders like D...

MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
By Mateen Dalal

The BNPL (book now pay later) payment has been introduced on MakeMyTrip on bookings for flights, travel, or hotels as well as on the Goibibo app MakeMyTrip, the online travel company, has recently said that it has collaborated with 15 banks, finte...

BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
By Mateen Dalal

BlackBerry Limited, a Canada-based software company focused on cybersecurity, has recently entered into a partnership with Midis Group, a leading technology company offering advanced hardware and software solutions, to expand its market footprint acr...